These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 282477)

  • 1. Erythromycin estolate-induced hepatitis. Ultrastructural study of liver.
    Gafter U; Mandel EM; Weiss S; Djaldetti M
    N Y State J Med; 1979 Jan; 79(1):87-9. PubMed ID: 282477
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cholestatic hepatitis caused by erythromycin estolate].
    García Monzón C; Noguerado A; Hidalgo S; Escudero V
    Rev Clin Esp; 1985 Nov; 177(8):420-1. PubMed ID: 3836470
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA begins proceedings to remove erythromycin estolate from market.
    FDA Drug Bull; 1979 Nov; 9(5):26-7. PubMed ID: 510836
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk-benefit equation for erythromycin estolate.
    LeBel M
    Am J Hosp Pharm; 1980 Feb; 37(2):176, 180. PubMed ID: 7361788
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hepatitis caused by various derivatives of erythromycin].
    Funck-Brentano C; Pessayre D; Benhamou JP
    Gastroenterol Clin Biol; 1983 Apr; 7(4):362-9. PubMed ID: 6347792
    [No Abstract]   [Full Text] [Related]  

  • 6. Ilosone update.
    Culp ER
    Am Fam Physician; 1980 Apr; 21(4):23. PubMed ID: 7377065
    [No Abstract]   [Full Text] [Related]  

  • 7. [Controlled study of the liver-protective effect of cycloxilic acid in a form of iatrogenic liver disease].
    Neuman M; Fluteau G
    Clin Ter; 1978 Nov; 87(3):243-64. PubMed ID: 380876
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate.
    Keeffe EB; Reis TC; Berland JE
    Dig Dis Sci; 1982 Aug; 27(8):701-4. PubMed ID: 6980110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythromycin propionate and estolate.
    Farre M
    Lancet; 1988 Jul; 2(8601):45. PubMed ID: 2898648
    [No Abstract]   [Full Text] [Related]  

  • 10. [Erythromycin-induced hepatitis].
    Perrier M; Portier G; de Calan L; Favre JP; Ozoux JP; Rivallain B; Brizon J
    Cah Anesthesiol; 1987; 35(3):237. PubMed ID: 3621021
    [No Abstract]   [Full Text] [Related]  

  • 11. Selection of an oral erythromycin product.
    Fraser DG
    Am J Hosp Pharm; 1980 Sep; 37(9):1199-205. PubMed ID: 6998290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [On the article of J. Buchanec and V. Kdrajnák: Lesions of the liver during therapy with erythromycin in 3 children].
    Rouzica M; Filipová K
    Cesk Pediatr; 1975 Jan; 30(1-2):71. PubMed ID: 1132045
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hepatotoxicity from erythromycin estolate].
    Saiz Santos S; Montero López L
    Aten Primaria; 1992 Dec; 10(9):1050. PubMed ID: 1467424
    [No Abstract]   [Full Text] [Related]  

  • 14. Erythromycin hepatotoxicity. A rare cause of a false-positive technetium-99m DISIDA study.
    Swayne LC; Kolc J
    Clin Nucl Med; 1986 Jan; 11(1):10-2. PubMed ID: 3943237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatotoxicity of erythromycin derivatives.
    Pessayre D; Benhamou JP
    Br Med J; 1979 May; 1(6174):1357. PubMed ID: 445081
    [No Abstract]   [Full Text] [Related]  

  • 16. Jaundice due to erythromycin estolate.
    Lunzer MR; Huang SN; Ward KM; Sherlock S
    Gastroenterology; 1975 May; 68(5 Pt 1):1284-91. PubMed ID: 1126604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholestatic hepatitis caused by esters of erythromycin and oleandomycin. 1962.
    Gilbert FI
    Hawaii Med J; 1995 Jun; 54(6):603-5. PubMed ID: 7642362
    [No Abstract]   [Full Text] [Related]  

  • 18. Case study: Drug interference in clinical chemistry.
    Hansen JL; Swanson LN
    Am J Med Technol; 1981 Mar; 47(3):189-91. PubMed ID: 7223765
    [No Abstract]   [Full Text] [Related]  

  • 19. [Erythromycin].
    Simmen HP; Siegenthaler W; Lüthy R
    Dtsch Med Wochenschr; 1982 Oct; 107(39):1480-2. PubMed ID: 7117164
    [No Abstract]   [Full Text] [Related]  

  • 20. Protective role of tetrahydrocurcumin against erythromycin estolate-induced hepatotoxicity.
    Pari L; Murugan P
    Pharmacol Res; 2004 May; 49(5):481-6. PubMed ID: 14998559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.